The Nifty Pharma index touched a fresh 52-week high of 25,043.15 on Wednesday, May 20, rising 0.7% intraday against a previous close of 24,867 on the NSE, even as the Sensex shed 0.67% and broader markets stayed under pressure from geopolitical tensions and foreign outflows. Two earnings-driven moves powered the rally: Mankind Pharma up 3.4% to ₹2,579.50 intraday, and Zydus Lifesciences surging 7% to ₹1,093.65. Both reported Q4 FY26 results the previous evening.
Mankind’s EBITDA Jump Is the Story Most Headlines Missed
Check Here: MANKIND PHARMA NSE Stock Price Today
Mankind Pharma posted Q4 FY26 consolidated PAT of ₹559 crore, up 30.4% year-on-year from ₹429 crore, on revenue of ₹3,443 crore, an 11.8% jump. That’s a clean beat. But the real number is EBITDA: ₹930 crore, up 36.1% year-on-year from ₹683 crore, with operating margin expanding 478 basis points to 27% from 22.2% a year ago. EBITDA grew at three times the rate of revenue. That kind of operating leverage doesn’t happen by accident; it reflects a better product mix, chronic therapy pricing power, and BSV integration discipline.
The domestic segment, which accounts for 85% of consolidated revenue, grew 13.4% to ₹2,886 crore, led by cardiac and anti-diabetes formulations. For the full consolidated year FY26, revenue reached ₹14,278 crore, up 17% year-on-year, with adjusted EBITDA margin at 25.4% and net debt-to-EBITDA improving to 1.1x.
What stood out was a board disclosure buried under the results: Executive Chairman Ramesh Juneja and CEO Sheetal Arora voluntarily waived their commission for FY26 to strengthen the company’s cash position ahead of its next expansion phase. The board simultaneously approved a ₹500 crore capital infusion into subsidiary Mankind Medicare, its largest single capital commitment this quarter, signalling an aggressive push on domestic manufacturing capacity. Morgan Stanley maintains an Overweight rating with a ₹2,500 target, citing improving execution and BSV recovery.
Zydus Delivered Margin Expansion — Then Announced a ₹1,100 Crore Buyback
Also Read: ZYDUS LIFESCIENCES NSE Stock Price Today
Zydus Lifesciences‘ Q4 FY26 numbers were solid across every line. Revenue rose 16% to ₹7,587 crore. Consolidated net profit came in at ₹1,272.5 crore, up 8.7% year-on-year. EBITDA reached ₹2,554 crore, up 20% annually, with operating margin expanding to 33.66% from 32.56% in Q4 FY25. Sequentially, EBITDA jumped 40.6% from ₹1,816 crore in Q3 FY26, a sharp single-quarter improvement.
The board then announced a ₹1,100 crore share buyback at ₹1,150 per share, a 16% premium to the May 18 closing price, with May 29 as the record date for shareholder eligibility. A 100% final dividend of Re 1 per share followed, with July 24 as the record date and payment by August 14 subject to AGM approval on August 11. For the full year FY26, Zydus revenue grew 16.8% to ₹27,148 crore, with R&D spend at ₹2,273 crore, representing 8.4% of revenues. Oddly, the stock opened 7% higher but pared to 5.52% by 9:27 AM, the buyback is generous; the partial pullback is likely profit booking from short-term holders.
The Rupee Did Its Part
India’s rupee hit its 9th consecutive record low against the US dollar on May 20. For pharma exporters with significant US generics businesses, rupee depreciation is a direct earnings tailwind, every rupee that weakens translates into higher realisations when dollar revenue is converted back. Laurus Labs, Piramal Pharma, Aurobindo Pharma, Biocon, and IPCA Laboratories all made the gainers list Wednesday on the back of this combined sentiment.
Not everyone participated. Gland Pharma, Ajanta Pharma, JB Chemicals & Pharma, Torrent Pharma, and Dr Reddy’s ended in the red, confirming that company-specific dynamics (US FDA exposure, domestic-export mix, pipeline news) can override even a strong sectoral tailwind.
The Performance Gap Versus Benchmark Is Now Impossible to Ignore
The Nifty Pharma index is up 9.8% year-to-date in 2026, has gained 4% in the last five trading sessions, and has delivered over 15% in the past year. The Nifty 50, in comparison, has lost 3% in the past month and is flat over the last five sessions. Wednesday’s 52-week high of 25,043 represents an 18.4% recovery from the 52-week low of 21,149.90. Over five years, Nifty Pharma has returned 77%; over three years, 105%. Any portfolio manager underweighting pharma against these numbers needs a clear explanation.
What to Watch at Mankind’s 12 PM Concall
Mankind’s investor concall was scheduled for today at 12 PM IST. Two specific questions matter most: whether management upgrades FY27 EBITDA margin guidance above the FY26 exit rate of 27% and what the integration timeline looks like for BSV after the ₹500 crore Mankind Medicare commitment. The NCD overhang, ₹1,250 crore already redeemed, another ₹1,250 crore maturing in October 2026, is the third line of questioning. Zydus semaglutide launches (Semaglyn, Mashema, and Alterme) in co-marketing with Lupin and Torrent are the other FY27 forward triggers; obesity and diabetes therapy is the fastest-growing segment globally in pharma right now, per IQVIA data; and Zydus has a first-mover advantage in India with its indigenously developed Aflibercept biosimilar Anyra.
Read Next: TCS, Infosys Hit 5-Year Lows as OpenAI Kills Headcount Model
Frequently Asked Questions
Q1. Why did Nifty Pharma hit a 52-week high on May 20 when broader markets were falling?
Nifty Pharma rose 0.7% intraday to 25,043.15 on May 20, driven by strong Q4 FY26 earnings from Mankind Pharma (PAT +30.4%, EBITDA +36.1%) and Zydus Lifesciences (revenue +16%, EBITDA +20%). The rupee hitting its 9th consecutive record low against the dollar added a tailwind for export-oriented companies. The Sensex fell 0.67% on the same day. The pharma index has now gained 9.8% year-to-date in 2026, outperforming the Nifty50, which is flat to negative over the same period.
Q2. What is the Zydus Lifesciences buyback price, size, and record date for May 2026?
Zydus announced a ₹1,100 crore share buyback at ₹1,150 per share, a 16% premium to the May 18 closing price, with May 29, 2026, as the record date for shareholder eligibility. The board also recommended a 100% final dividend of Re 1 per equity share for FY26, with a July 24, 2026, record date and payment by August 14, 2026, subject to AGM approval on August 11.
Q3. What drove Mankind Pharma’s Q4 FY26 EBITDA margin expansion to 27 percent?
Mankind’s Q4 FY26 EBITDA jumped 36.1% to ₹930 crore, with margin expanding 478 basis points to 27% from 22.2% in Q4 FY25. The primary drivers were a better product mix weighted toward chronic therapies (cardiac and anti-diabetes), operating leverage from 13.4% domestic revenue growth to ₹2,886 crore, and BSV’s specialty portfolio scaling. Revenue grew 11.8% to ₹3,443 crore while EBITDA grew at three times that rate, a clear sign of cost discipline and pricing power in the domestic branded generics business.
